Pathology and disease mechanisms in different stages of multiple sclerosis.
about
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionNew Insights into the Role of Oxidative Stress Mechanisms in the Pathophysiology and Treatment of Multiple SclerosisImaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple SclerosisTh1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes.Advanced MRI unravels the nature of tissue alterations in early multiple sclerosisThe extracellular domain of myelin oligodendrocyte glycoprotein elicits atypical experimental autoimmune encephalomyelitis in rat and Macaque speciesDifferentiation and quantification of inflammation, demyelination and axon injury or loss in multiple sclerosis.Intrinsic functional plasticity of the sensorimotor network in relapsing-remitting multiple sclerosis: evidence from a centrality analysisSevere inflammatory disease activity 14 months after cessation of Natalizumab in a patient with Leber's optic neuropathy and multiple sclerosis - a case reportSmall heat shock proteins are induced during multiple sclerosis lesion development in white but not grey matter.Intrinsic Functional Plasticity of the Thalamocortical System in Minimally Disabled Patients with Relapsing-Remitting Multiple SclerosisPREVAIL: Predicting Recovery through Estimation and Visualization of Active and Incident Lesions.Are Modular Activations Altered in Lower Limb Muscles of Persons with Multiple Sclerosis during Walking? Evidence from Muscle Synergies and Biomechanical AnalysisAssessment of Serum Nitrogen Species and Inflammatory Parameters in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different Therapeutic ApproachesGut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus.Multiple sclerosis treatment and infectious issues: update 2013.Relapsing and progressive forms of multiple sclerosis: insights from pathology.Mitochondrial dysfunction in central nervous system white matter disorders.STAT3 represents a molecular switch possibly inducing astroglial instead of oligodendroglial differentiation of oligodendroglial progenitor cells in Theiler's murine encephalomyelitis.Inflammatory demyelination alters subcortical visual circuits.The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Correlation of geographic distributions of haptoglobin alleles with prevalence of multiple sclerosis (MS) - a narrative literature review.Role of Oligodendrocyte Dysfunction in Demyelination, Remyelination and Neurodegeneration in Multiple Sclerosis.Neural Stem Cell-Based Regenerative Approaches for the Treatment of Multiple Sclerosis.Oligodendrocytes engineered with migratory proteins as effective graft source for cell transplantation in multiple sclerosis.Distinctive Roles for α7*- and α9*-Nicotinic Acetylcholine Receptors in Inflammatory and Autoimmune Responses in the Murine Experimental Autoimmune Encephalomyelitis Model of Multiple SclerosisResolving the clinico-radiological paradox in multiple sclerosis.The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy.Protective effects of erythropoietin against cuprizone-induced oxidative stress and demyelination in the mouse corpus callosum.Dynamics and heterogeneity of brain damage in multiple sclerosis.Protective effects of melatonin against mitochondrial injury in a mouse model of multiple sclerosis.In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis.The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis.Netrin-1 and multiple sclerosis: a new biomarker for neuroinflammation?Pathogenic inflammation in the CNS of mice carrying human PLP1 mutations.Multiple sclerosis: Oral laquinimod for MS--bringing the brain into focus.Shuttling Tolerogenic Dendritic Cells across the Blood-Brain Barrier In Vitro via the Introduction of De Novo C-C Chemokine Receptor 5 Expression Using Messenger RNA Electroporation.MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes.Circulating IGF-1, IGFB-3, GH and TSH levels in multiple sclerosis and their relationship with treatment.
P2860
Q26822611-A47073F0-2DAF-493F-ABC8-A14F4CD43D4FQ28072844-0507AC35-C69E-4D19-BA1C-FC86EEE16E94Q28267527-56B91303-203F-43B9-AB64-343E256FA5D7Q33855341-A3D7089B-B8F0-423B-9C8C-D8779A62F576Q34286763-06760FDB-6915-45FA-87EE-8F4FDDABD1C4Q34323535-B8038AAE-F299-4F89-ADA6-F1F556709A21Q35529707-FE1FBE21-BF08-4812-8A1F-9D71BF402986Q35673922-0D6D2211-CCAF-44BD-9A0B-75B27DFFFD24Q36166706-2429ED63-2A51-4CA9-BBDC-ACBF1B0BF53BQ36398055-7AAC844E-AA33-464A-B2E7-54EEBE2F00E4Q36497227-28ECC1F3-88C3-49EA-993E-D9A0CEEED9B2Q37172628-0E98F1A2-5A01-4264-97FD-C6FCF9402E8BQ37486630-0DF132CF-1F6D-4894-83EF-B864F839DE76Q37548170-24F4DD88-A0C1-49F7-8AB8-BF3E5125167BQ37698703-E224409F-7747-4815-90C3-9F219267F72BQ38153471-1C2AD2AD-13C1-44DC-B9A4-EA0D2609C51AQ38203770-FB88EE51-C182-4002-9DA6-9DA328112E02Q38215315-87DDB152-8AE6-494C-9EA1-0054C8C6AF03Q38478956-5E1D0470-3D56-4100-8A43-8C800A7BA066Q38618188-4552E46D-68EC-439E-A24C-74EDDD68D295Q38767477-6F4815F1-D82B-426E-BB1E-A0D1484A37A2Q38837294-09A51CF0-0A70-4500-8F6C-B4FBF42FCC33Q38997128-258E1217-F024-4AD3-967E-99ED27CAC3E2Q39091396-A4600A0B-9A0B-4A89-8157-FDC5A024A28AQ39279957-5338887B-7760-4EA0-AEDD-555D1FCBEDC0Q41812779-6DB5E3F4-C815-43B5-83E5-8B0ECEB03683Q42042326-8106AF81-5159-4F16-BBA6-D930E5D82957Q43297894-05E320AB-E2AF-4201-A260-CD82C10AE40AQ43375909-4140614E-2236-41DA-9748-B0A4168723BAQ43807948-01A0B76A-95D0-4846-A6C7-E895D43DB601Q46259503-C0B35197-94AD-4131-97AC-4C262A09182CQ46290321-D568F2B6-C464-4FED-BF52-2B54CBAC6420Q47425888-415A7FB8-2E42-49AF-BC39-DBA57C00860AQ47579410-30921285-11B7-42D3-82E6-385014758DE2Q48176135-9356A7A2-B06E-4A91-9AB5-22CAE3794FEDQ48319833-A427362B-6CF0-42B0-A869-F780B405D8BFQ48846829-513ED332-8822-460A-8DDD-5A9A3BACEDB3Q49906660-B1E44CA5-A292-4D3E-9C7A-974FF11C7BACQ50692674-6E70FEAA-23FB-4D76-9455-DF78C01A775BQ51025655-795E0083-04FF-4A70-81EC-D77F587C1FE5
P2860
Pathology and disease mechanisms in different stages of multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pathology and disease mechanisms in different stages of multiple sclerosis.
@en
type
label
Pathology and disease mechanisms in different stages of multiple sclerosis.
@en
prefLabel
Pathology and disease mechanisms in different stages of multiple sclerosis.
@en
P1476
Pathology and disease mechanisms in different stages of multiple sclerosis.
@en
P356
10.1016/J.JNS.2013.05.010
P577
2013-06-02T00:00:00Z